Clinical trial results:
An Open-Label, Uncontrolled 4-Week Study to Assess the Safety, Efficacy and Pharmacokinetics of Allegra® (dry Syrup Formulation) 15 mg or 30 mg Twice Daily in Pediatric Patients With Perennial Allergic Rhinitis.

Summary

EudraCT number	2017-000239-15
Trial protocol	Outside EU/EEA
Global end of trial date	13 August 2011

Results information

Result version number	v1 (current)
This version publication date	25 June 2017
First version publication date	25 June 2017

Trial information

Trial identification

Sponsor protocol code	SFY10717

Additional study identifiers

ISRCTN number	-
ClinicalTrials.gov id (NCT number)	NCT01244217
WHO universal trial number (UTN)	U1111-1115-3842

Notes:

Sponsors

Sponsor organisation name	Sanofi Aventis Recherche & Developpement
Sponsor organisation address	1 avenue Pierre Brossolette, Chilly--Mazarin, France, 91380
Public contact	Trial Transparency Team, Sanofi Aventis Recherche & Developpement, Contact-US@sanofi.com
Scientific contact	Trial Transparency Team, Sanofi Aventis Recherche & Developpement, Contact-US@sanofi.com

Notes:

Paediatric regulatory details

Is trial part of an agreed paediatric investigation plan (PIP)	No
Does article 45 of REGULATION (EC) No 1901/2006 apply to this trial?	No
Does article 46 of REGULATION (EC) No 1901/2006 apply to this trial?	Yes

Notes:

Results analysis stage

Analysis stage	Final
Date of interim/final analysis	08 September 2011
Is this the analysis of the primary completion data?	No

Global end of trial reached?	Yes
Global end of trial date	13 August 2011
Was the trial ended prematurely?	No

Notes:

General information about the trial

Main objective of the trial:

To evaluate the safety of fexofenadine hydrochloride (HCl) (dry syrup formulation) when administered for 4 weeks at doses of 15 mg or 30 mg twice daily to pediatric subjects 6 months through 11 years of age with perennial allergic rhinitis (PAR).

Protection of trial subjects:

The study was conducted by investigators experienced in the treatment of pediatric subjects. The parent(s) or guardian(s) as well as the children were fully informed of all pertinent aspects of the clinical trial as well as the possibility to discontinue at any time. In addition to the consent form for the parent(s)/guardian(s), an assent form in child-appropriate language was provided and explained to the child. Repeated invasive procedures were minimized. The number of blood samples as well as the amount of blood drawn were adjusted according to age and weight. A topical anesthesia may have been used to minimize distress and discomfort.

Background therapy: -

Evidence for comparator: -

Actual start date of recruitment	27 October 2010
Long term follow-up planned	No
Independent data monitoring committee (IDMC) involvement?	No

Notes:

Population of trial subjects

Subjects enrolled per country

Country: Number of subjects enrolled	Japan: 109
Worldwide total number of subjects	109
EEA total number of subjects	0

Notes:

Subjects enrolled per age group

In utero	0
Preterm newborn - gestational age < 37 wk	0
Newborns (0-27 days)	0
Infants and toddlers (28 days-23 months)	7
Children (2-11 years)	102
Adolescents (12-17 years)	0
Adults (18-64 years)	0

From 65 to 84 years	0
85 years and over	0

Subject disposition

Recruitment

Recruitment details:

The study was conducted at 15 centres in Japan from 27 October 2010 to 16 May 2011.

Pre-assignment

Screening details:

Out of 199 subjects screened, 90 were screen failures and 109 subjects were enrolled and treated in this study. The study had two treatment periods: 4-weeks main treatment period and an 8-weeks extension treatment period. Subjects who completed 4-weeks main treatment period and required continuous treatment, entered the extension treatment period.

Period 1

Period 1 title	Overall study (overall period)
Is this the baseline period?	Yes
Allocation method	Not applicable
Blinding used	Not blinded

Arms

Are arms mutually exclusive?	Yes
Arm title	Age 6 Months to <2 Years

Arm description:

Subjects aged 6 months to <2 years, received one sachet of 15 mg fexofenadine HCl with water or suspended in water or lukewarm water twice daily (in the morning and evening) up to 12 weeks.

Arm type	Experimental
Investigational medicinal product name	Fexofenadine HCl
Investigational medicinal product code	M016455
Other name	Allegra®
Pharmaceutical forms	Powder for oral suspension
Routes of administration	Oral use

Dosage and administration details:

One sachet of 15 mg fexofenadine HCl with water or suspended in water or lukewarm water twice daily (in the morning and evening).

Arm title	Age 2 to <7 Years

Arm description:

Subjects aged 2 to <7 years, received one sachet of 30 mg fexofenadine HCl (if body weight >10.5 kg) or 15 mg fexofenadine HCl (if body weight <=10.5 kg) with water or suspended in water or lukewarm water twice daily (in the morning and evening) up to 12 weeks.

Arm type	Experimental
Investigational medicinal product name	Fexofenadine HCl
Investigational medicinal product code	M016455
Other name	Allegra®
Pharmaceutical forms	Powder for oral suspension
Routes of administration	Oral use

Dosage and administration details:

One sachet of 30 mg fexofenadine HCl or 15 mg fexofenadine HCl with water or suspended in water or lukewarm water twice daily (in the morning and evening).

Arm title	Age 7 to 11 Years

Arm description:

Subjects aged 7 to 11 years, received one sachet of 30 mg fexofenadine HCl (if body weight >10.5 kg) or 15 mg fexofenadine HCl (if body weight <=10.5 kg) with water or suspended in water or lukewarm water twice daily (in the morning and evening) up to 12 weeks.

Arm type	Experimental

Investigational medicinal product name	Fexofenadine HCl
Investigational medicinal product code	M016455
Other name	Allegra®
Pharmaceutical forms	Powder for oral suspension
Routes of administration	Oral use

Dosage and administration details:

One sachet of 30 mg fexofenadine HCl or 15 mg fexofenadine HCl with water or suspended in water or lukewarm water twice daily (in the morning and evening).

Number of subjects in period 1	Age 6 Months to <2 Years	Age 2 to <7 Years	Age 7 to 11 Years
Started	7	51	51
Completed 4-Week Main Treatment Period	7	51	51
Entered 8-Week Extension Period	6	46	50
Completed	6	46	49
Not completed	1	5	2
Consent withdrawn by subject	-	-	1
Did not enter 8-week extension phase	1	5	1

Baseline characteristics

Reporting groups	
Reporting group title	Age 6 Months to <2 Years
Reporting group description:	
Subjects aged 6 months to <2 years, received one sachet of 15 mg fexofenadine HCl with water or suspended in water or lukewarm water twice daily (in the morning and evening) up to 12 weeks.	
Reporting group title	Age 2 to <7 Years
Reporting group description:	
Subjects aged 2 to <7 years, received one sachet of 30 mg fexofenadine HCl (if body weight >10.5 kg) or 15 mg fexofenadine HCl (if body weight <=10.5 kg) with water or suspended in water or lukewarm water twice daily (in the morning and evening) up to 12 weeks.	
Reporting group title	Age 7 to 11 Years
Reporting group description:	
Subjects aged 7 to 11 years, received one sachet of 30 mg fexofenadine HCl (if body weight >10.5 kg) or 15 mg fexofenadine HCl (if body weight <=10.5 kg) with water or suspended in water or lukewarm water twice daily (in the morning and evening) up to 12 weeks.	

Reporting group values	Age 6 Months to <2 Years	Age 2 to <7 Years	Age 7 to 11 Years
Number of subjects	7	51	51
Age categorical Units: Subjects			
Age continuous Units: years arithmetic mean standard deviation	 1 ± 0	 4.4 ± 1.3	 8.8 ± 1.3
Gender categorical Units: Subjects			
Female	3	18	16
Male	4	33	35

Reporting group values	Total		
Number of subjects	109		
Age categorical Units: Subjects			
Age continuous Units: years arithmetic mean standard deviation	 -	 	
Gender categorical Units: Subjects			
Female	37		
Male	72		

End points

End points reporting groups

Reporting group title	Age 6 Months to <2 Years

Reporting group description:

Subjects aged 6 months to <2 years, received one sachet of 15 mg fexofenadine HCl with water or suspended in water or lukewarm water twice daily (in the morning and evening) up to 12 weeks.

Reporting group title	Age 2 to <7 Years

Reporting group description:

Subjects aged 2 to <7 years, received one sachet of 30 mg fexofenadine HCl (if body weight >10.5 kg) or 15 mg fexofenadine HCl (if body weight <=10.5 kg) with water or suspended in water or lukewarm water twice daily (in the morning and evening) up to 12 weeks.

Reporting group title	Age 7 to 11 Years

Reporting group description:

Subjects aged 7 to 11 years, received one sachet of 30 mg fexofenadine HCl (if body weight >10.5 kg) or 15 mg fexofenadine HCl (if body weight <=10.5 kg) with water or suspended in water or lukewarm water twice daily (in the morning and evening) up to 12 weeks.

Primary: Number of Subjects With Adverse Events (AEs) Up to 4 Weeks

End point title	Number of Subjects With Adverse Events (AEs) Up to 4

End point description:

AEs were any unfavorable and unintended sign, symptom, syndrome, or illness observed by the investigator or reported by the subject/ guardian during the study. Safety population consisted of all treated subjects.

End point type	Primary

End point timeframe:

From first dose of study drug up to 4 weeks

Notes:

[1] - No statistical analyses have been specified for this primary end point. It is expected there is at least one statistical analysis for each primary end point.
Justification: As the endpoint is descriptive in nature, no statistical analysis is provided.

End point values	Age 6 Months to <2 Years	Age 2 to <7 Years	Age 7 to 11 Years	
Subject group type	Reporting group	Reporting group	Reporting group	
Number of subjects analysed	7	51	51	
Units: subjects	2	39	28	

Statistical analyses

No statistical analyses for this end point

Primary: Number of Subjects With Potentially Clinically Significant Laboratory Abnormalities up to 4 Weeks: Safety Population

End point title	Number of Subjects With Potentially Clinically Significant Laboratory Abnormalities up to 4 Weeks: Safety Population[2]

End point description:

Laboratory parameters used were related to renal functions (creatinine) and liver functions (alanine

transaminase, aspartate aminotransferase, bilirubin). Subjects with potentially clinically significant laboratory abnormalities were as determined by sponsor. Analysis was performed on safety population defined as all treated subjects.

End point type	Primary

End point timeframe:

Baseline up to 4 weeks

Notes:

[2] - No statistical analyses have been specified for this primary end point. It is expected there is at least one statistical analysis for each primary end point.
Justification: As the endpoint is descriptive in nature, no statistical analysis is provided.

End point values	Age 6 Months to <2 Years	Age 2 to <7 Years	Age 7 to 11 Years	
Subject group type	Reporting group	Reporting group	Reporting group	
Number of subjects analysed	7	51	51	
Units: subjects				
Creatinine	0	2	0	
Alanine Transaminase	0	0	0	
Aspartate Aminotransferase	0	0	0	
Bilirubin	0	0	0	

Statistical analyses

No statistical analyses for this end point

Primary: Number of Subjects With Potentially Clinically Significant Laboratory Abnormalities up to 4 Weeks: For Subjects Aged 2 to 11 Years

End point title	Number of Subjects With Potentially Clinically Significant Laboratory Abnormalities up to 4 Weeks: For Subjects Aged 2 to 11 Years[3][4]

End point description:

Laboratory parameters used were related to hematology (hemoglobin, hematocrit, red blood cell count, platelets count, white blood cell count), renal functions (blood urea nitrogen) and liver functions (alkaline phosphatase). Subjects with potentially clinically significant laboratory abnormalities were as determined by sponsor. Analysis was performed on a subset of safety population (defined as all treated subjects) consisted of subjects aged 2 to 11 years.

End point type	Primary

End point timeframe:

Baseline up to 4 weeks

Notes:

[3] - No statistical analyses have been specified for this primary end point. It is expected there is at least one statistical analysis for each primary end point.
Justification: As the endpoint is descriptive in nature, no statistical analysis is provided.

[4] - The end point is not reporting statistics for all the arms in the baseline period. It is expected all the baseline period arms will be reported on when providing values for an end point on the baseline period.
Justification: For this endpoint, data was reported only for the subjects above 2 years of age.

End point values	Age 2 to <7 Years	Age 7 to 11 Years		
Subject group type	Reporting group	Reporting group		
Number of subjects analysed	51	51		
Units: subjects				
Hemoglobin	1	1		
Hematocrit	10	4		
Red Blood Cell Count	0	0		
Platelets	0	0		
White Blood Cell Count	0	0		
Blood Urea Nitrogen	0	0		
Alkaline Phosphatase	0	0		

Statistical analyses

No statistical analyses for this end point

Secondary: Number of Subjects With Adverse Events up to 12 Weeks

End point title	Number of Subjects With Adverse Events up to 12 Weeks

End point description:

AEs were any unfavorable and unintended sign, symptom, syndrome, or illness observed by the investigator or reported by the subject/ guardian during the study. Safety population consisted of all treated subjects.

End point type	Secondary

End point timeframe:

From first dose of study drug up to 12 weeks

End point values	Age 6 Months to <2 Years	Age 2 to <7 Years	Age 7 to 11 Years	
Subject group type	Reporting group	Reporting group	Reporting group	
Number of subjects analysed	7	51	51	
Units: subjects	6	46	38	

Statistical analyses

No statistical analyses for this end point

Secondary: Number of Subjects With Potentially Clinically Significant Laboratory Abnormalities up to 12 Weeks: Safety Population

End point title	Number of Subjects With Potentially Clinically Significant Laboratory Abnormalities up to 12 Weeks: Safety Population

End point description:

Laboratory parameters used were related to renal functions (creatinine) and liver functions (alanine transaminase, aspartate aminotransferase, bilirubin). Subjects with potentially clinically significant laboratory abnormalities were as determined by sponsor. Analysis was performed on safety population defined as all treated subjects.

End point type	Secondary

End point timeframe:

Baseline up to 12 weeks

End point values	Age 6 Months to <2 Years	Age 2 to <7 Years	Age 7 to 11 Years	
Subject group type	Reporting group	Reporting group	Reporting group	
Number of subjects analysed	7	51	51	
Units: subjects				
Creatinine	0	2	1	
Alanine Transaminase	0	0	0	
Aspartate Aminotransferase	0	0	0	
Bilirubin	0	0	0	

Statistical analyses

No statistical analyses for this end point

Secondary: Number of Subjects With Potentially Clinically Significant Laboratory Abnormalities up to 12 Weeks: For Subjects Aged 2 to 11 Years

End point title	Number of Subjects With Potentially Clinically Significant Laboratory Abnormalities up to 12 Weeks: For Subjects Aged 2 to 11 Years[5]

End point description:

Laboratory parameters used were related to hematology (hemoglobin, hematocrit, red blood cell count, platelets count, white blood cell count), renal functions (blood urea nitrogen) and liver functions (alkaline phosphatase). Subjects with potentially clinically significant laboratory abnormalities were as determined by sponsor. Analysis was performed on a subset of safety population (defined as all treated subjects) consisted of subjects aged 2 to 11 years.

End point type	Secondary

End point timeframe:

Baseline up to 12 weeks

Notes:

[5] - The end point is not reporting statistics for all the arms in the baseline period. It is expected all the baseline period arms will be reported on when providing values for an end point on the baseline period.
Justification: For this endpoint, data was reported only for the subjects above 2 years of age.

End point values	Age 2 to <7 Years	Age 7 to 11 Years		
Subject group type	Reporting group	Reporting group		
Number of subjects analysed	51	51		
Units: subjects				
Hemoglobin	1	1		
Hematocrit	18	7		
Red Blood Cell Count	0	0		
Platelets	0	0		
White Blood Cell Count	0	1		
Blood Urea Nitrogen	0	0		
Alkaline Phosphatase	0	0		

Statistical analyses

No statistical analyses for this end point

Secondary: Change From Baseline in Average Total Nasal Symptom Scores (TNSS) Through Week 4 on Subject Diary

End point title	Change From Baseline in Average Total Nasal Symptom Scores (TNSS) Through Week 4 on Subject Diary[6]

End point description:

Subject's guardian assessed nasal symptoms using assessment criteria of nasal symptom severity. The guardian observed child's condition as well as listening to child's complaints about nasal symptoms, and then entered nasal symptom scores in subject's diary. TNSS was assessed based on the scores of 3 individual nasal symptoms as: paroxysmal sneezing, nasal discharge and nasal congestion. Each symptom was scored on a 5-point scale ranges from 0=no symptoms to 4=severe symptoms. TNSS was derived from the sum of scores from each individual symptoms and ranges from 0=best outcome to 12=worst outcome. A higher score indicated worse disease status, and a negative change from baseline indicated improvement. Analysis was performed on modified intention-to-treat (mITT) population defined as all registered subjects whose total scores of 3 nasal symptoms for subjects aged 2 years & older or nasal findings for subjects aged <2 years both baseline & post treatment were available.

End point type	Secondary

End point timeframe:

Baseline through Week 4

Notes:

[6] - The end point is not reporting statistics for all the arms in the baseline period. It is expected all the baseline period arms will be reported on when providing values for an end point on the baseline period.
Justification: For this endpoint, data was reported only for the subjects above 2 years of age.

End point values	Age 2 to <7 Years	Age 7 to 11 Years		
Subject group type	Reporting group	Reporting group		
Number of subjects analysed	51	51		
Units: scores on a scale				
arithmetic mean (standard deviation)	-1.63 (± 1.99)	-1.92 (± 1.77)		

Statistical analyses

No statistical analyses for this end point

Secondary: Change From Baseline in Total Nasal Symptom Severity Scores (TNSSS) Assessed by Investigator or Sub-Investigator at Week 2 and 4

End point title	Change From Baseline in Total Nasal Symptom Severity Scores (TNSSS) Assessed by Investigator or Sub-Investigator at Week 2 and 4[7]

End point description:

TNSSS was assessed by the investigator, sub-investigator and was based on the scores of 3 individual nasal symptoms (paroxysmal sneezing, nasal discharge, and nasal congestion), in view of physical examinations and nasal findings. Each symptom was scored on a 5-point scale ranges from 0=no symptoms to 4=severe symptoms. TNSS was derived from the sum of scores from each individual

symptoms and ranges from 0=best outcome to 12=worst outcome. A higher score indicated worse disease status, and a negative change from baseline indicated improvement. Analysis was performed on modified intention-to-treat (mITT) population defined as all registered subjects whose total scores of 3 nasal symptoms for subjects aged 2 years & older or nasal findings for subjects aged <2 years both baseline & post treatment were available.

End point type	Secondary

End point timeframe:

Baseline, Week 2, Week 4

Notes:

[7] - The end point is not reporting statistics for all the arms in the baseline period. It is expected all the baseline period arms will be reported on when providing values for an end point on the baseline period.
Justification: For this endpoint, data was reported only for the subjects above 2 years of age.

End point values	Age 2 to <7 Years	Age 7 to 11 Years		
Subject group type	Reporting group	Reporting group		
Number of subjects analysed	51	51		
Units: scores on scale				
arithmetic mean (standard deviation)				
Week 2	-1.3 (± 2)	-1.7 (± 1.8)		
Week 4	-2.4 (± 1.8)	-2.4 (± 2.3)		

Statistical analyses

No statistical analyses for this end point

Adverse events

Adverse events information

Timeframe for reporting adverse events:

All AEs were collected from signature of the informed consent form up to the final visit (Day 89) regardless of seriousness or relationship to investigational product.

Adverse event reporting additional description:

Reported adverse events are treatment-emergent adverse events that is AEs that developed/worsened during the 'on treatment period' (time from first dose of study drug up to 5 days after the last dose of study drug).

Assessment type	Systematic

Dictionary used

Dictionary name	MedDRA
Dictionary version	14.0

Reporting groups

Reporting group title	Age 6 Months to <2 Years

Reporting group description:

Subjects aged 6 months to <2 years, received one sachet of 15 mg fexofenadine HCl with water or suspended in water or lukewarm water twice daily (in the morning and evening) up to 12 weeks.

Reporting group title	Age 2 to <7 Years

Reporting group description:

Subjects aged 2 to <7 years received one sachet of 30 mg fexofenadine HCl (if body weight >10.5 kg) or 15 mg fexofenadine HCl (if body weight <=10.5 kg) with water or suspended in water or lukewarm water twice daily (in the morning and evening) up to 12 weeks.

Reporting group title	Age 7 to 11 Years

Reporting group description:

Subjects aged 7 to 11 years received one sachet of 30 mg fexofenadine HCl (if body weight >10.5 kg) or 15 mg fexofenadine HCl (if body weight <=10.5 kg) with water or suspended in water or lukewarm water twice daily (in the morning and evening) up to 12 weeks.

Serious adverse events	Age 6 Months to <2 Years	Age 2 to <7 Years	Age 7 to 11 Years
Total subjects affected by serious adverse events			
subjects affected / exposed	0 / 7 (0.00%)	0 / 51 (0.00%)	0 / 51 (0.00%)
number of deaths (all causes)	0	0	0
number of deaths resulting from adverse events	0	0	0

Frequency threshold for reporting non-serious adverse events: 0 %

Non-serious adverse events	Age 6 Months to <2 Years	Age 2 to <7 Years	Age 7 to 11 Years
Total subjects affected by non-serious adverse events			
subjects affected / exposed	6 / 7 (85.71%)	46 / 51 (90.20%)	38 / 51 (74.51%)
General disorders and administration site conditions			

Pyrexia			
subjects affected / exposed	1 / 7 (14.29%)	7 / 51 (13.73%)	2 / 51 (3.92%)
occurrences (all)	1	7	2
Chest Discomfort			
subjects affected / exposed	0 / 7 (0.00%)	1 / 51 (1.96%)	0 / 51 (0.00%)
occurrences (all)	0	2	0
Immune system disorders			
Seasonal Allergy			
subjects affected / exposed	0 / 7 (0.00%)	1 / 51 (1.96%)	1 / 51 (1.96%)
occurrences (all)	0	1	1
Respiratory, thoracic and mediastinal disorders			
Epistaxis			
subjects affected / exposed	0 / 7 (0.00%)	9 / 51 (17.65%)	1 / 51 (1.96%)
occurrences (all)	0	10	2
Cough			
subjects affected / exposed	1 / 7 (14.29%)	2 / 51 (3.92%)	1 / 51 (1.96%)
occurrences (all)	1	2	1
Pharyngeal Erythema			
subjects affected / exposed	0 / 7 (0.00%)	2 / 51 (3.92%)	0 / 51 (0.00%)
occurrences (all)	0	2	0
Allergic Bronchitis			
subjects affected / exposed	0 / 7 (0.00%)	0 / 51 (0.00%)	1 / 51 (1.96%)
occurrences (all)	0	0	1
Oropharyngeal Pain			
subjects affected / exposed	0 / 7 (0.00%)	0 / 51 (0.00%)	1 / 51 (1.96%)
occurrences (all)	0	0	1
Investigations			
White Blood Cell Count Decreased			
subjects affected / exposed	0 / 7 (0.00%)	1 / 51 (1.96%)	0 / 51 (0.00%)
occurrences (all)	0	1	0
Injury, poisoning and procedural complications			
Contusion			
subjects affected / exposed	0 / 7 (0.00%)	0 / 51 (0.00%)	1 / 51 (1.96%)
occurrences (all)	0	0	1
Ear Abrasion			

subjects affected / exposed	0 / 7 (0.00%)	0 / 51 (0.00%)	1 / 51 (1.96%)
occurrences (all)	0	0	1
Foreign Body			
subjects affected / exposed	0 / 7 (0.00%)	1 / 51 (1.96%)	0 / 51 (0.00%)
occurrences (all)	0	1	0
Nervous system disorders			
Headache			
subjects affected / exposed	0 / 7 (0.00%)	3 / 51 (5.88%)	1 / 51 (1.96%)
occurrences (all)	0	3	1
Somnolence			
subjects affected / exposed	0 / 7 (0.00%)	2 / 51 (3.92%)	1 / 51 (1.96%)
occurrences (all)	0	2	1
Blood and lymphatic system disorders			
Lymphadenitis			
subjects affected / exposed	0 / 7 (0.00%)	1 / 51 (1.96%)	0 / 51 (0.00%)
occurrences (all)	0	1	0
Ear and labyrinth disorders			
Tympanic Membrane Disorder			
subjects affected / exposed	0 / 7 (0.00%)	2 / 51 (3.92%)	0 / 51 (0.00%)
occurrences (all)	0	2	0
Ear Pain			
subjects affected / exposed	0 / 7 (0.00%)	1 / 51 (1.96%)	0 / 51 (0.00%)
occurrences (all)	0	1	0
External Ear Pain			
subjects affected / exposed	0 / 7 (0.00%)	1 / 51 (1.96%)	0 / 51 (0.00%)
occurrences (all)	0	1	0
Eye disorders			
Conjunctivitis Allergic			
subjects affected / exposed	0 / 7 (0.00%)	1 / 51 (1.96%)	1 / 51 (1.96%)
occurrences (all)	0	1	1
Chalazion			
subjects affected / exposed	0 / 7 (0.00%)	1 / 51 (1.96%)	0 / 51 (0.00%)
occurrences (all)	0	1	0
Keratitis			
subjects affected / exposed	0 / 7 (0.00%)	0 / 51 (0.00%)	1 / 51 (1.96%)
occurrences (all)	0	0	1
Gastrointestinal disorders			

Vomiting			
subjects affected / exposed	0 / 7 (0.00%)	6 / 51 (11.76%)	1 / 51 (1.96%)
occurrences (all)	0	6	1
Diarrhoea			
subjects affected / exposed	0 / 7 (0.00%)	6 / 51 (11.76%)	0 / 51 (0.00%)
occurrences (all)	0	6	0
Abdominal Pain			
subjects affected / exposed	0 / 7 (0.00%)	1 / 51 (1.96%)	2 / 51 (3.92%)
occurrences (all)	0	1	2
Cheilitis			
subjects affected / exposed	0 / 7 (0.00%)	1 / 51 (1.96%)	1 / 51 (1.96%)
occurrences (all)	0	1	1
Constipation			
subjects affected / exposed	0 / 7 (0.00%)	1 / 51 (1.96%)	1 / 51 (1.96%)
occurrences (all)	0	1	1
Abdominal Pain Lower			
subjects affected / exposed	0 / 7 (0.00%)	1 / 51 (1.96%)	0 / 51 (0.00%)
occurrences (all)	0	1	0
Abdominal Pain Upper			
subjects affected / exposed	0 / 7 (0.00%)	1 / 51 (1.96%)	0 / 51 (0.00%)
occurrences (all)	0	1	0
Dental Caries			
subjects affected / exposed	0 / 7 (0.00%)	1 / 51 (1.96%)	0 / 51 (0.00%)
occurrences (all)	0	1	0
Nausea			
subjects affected / exposed	0 / 7 (0.00%)	0 / 51 (0.00%)	1 / 51 (1.96%)
occurrences (all)	0	0	1
Skin and subcutaneous tissue disorders			
Dermatitis			
subjects affected / exposed	0 / 7 (0.00%)	0 / 51 (0.00%)	1 / 51 (1.96%)
occurrences (all)	0	0	1
Dermatitis Allergic			
subjects affected / exposed	0 / 7 (0.00%)	1 / 51 (1.96%)	0 / 51 (0.00%)
occurrences (all)	0	1	0
Rash			

subjects affected / exposed	1 / 7 (14.29%)	0 / 51 (0.00%)	0 / 51 (0.00%)
occurrences (all)	1	0	0
Urticaria			
subjects affected / exposed	0 / 7 (0.00%)	1 / 51 (1.96%)	0 / 51 (0.00%)
occurrences (all)	0	1	0
Infections and infestations			
Nasopharyngitis			
subjects affected / exposed	4 / 7 (57.14%)	26 / 51 (50.98%)	22 / 51 (43.14%)
occurrences (all)	5	38	32
Influenza			
subjects affected / exposed	1 / 7 (14.29%)	6 / 51 (11.76%)	10 / 51 (19.61%)
occurrences (all)	1	6	10
Acute Sinusitis			
subjects affected / exposed	0 / 7 (0.00%)	5 / 51 (9.80%)	5 / 51 (9.80%)
occurrences (all)	0	8	6
Bronchitis			
subjects affected / exposed	0 / 7 (0.00%)	3 / 51 (5.88%)	3 / 51 (5.88%)
occurrences (all)	0	3	3
Gastroenteritis			
subjects affected / exposed	1 / 7 (14.29%)	2 / 51 (3.92%)	2 / 51 (3.92%)
occurrences (all)	1	2	2
Acute Tonsillitis			
subjects affected / exposed	0 / 7 (0.00%)	1 / 51 (1.96%)	2 / 51 (3.92%)
occurrences (all)	0	1	2
Erythema Infectiosum			
subjects affected / exposed	0 / 7 (0.00%)	2 / 51 (3.92%)	0 / 51 (0.00%)
occurrences (all)	0	2	0
Impetigo			
subjects affected / exposed	0 / 7 (0.00%)	2 / 51 (3.92%)	0 / 51 (0.00%)
occurrences (all)	0	2	0
Otitis Externa			
subjects affected / exposed	0 / 7 (0.00%)	1 / 51 (1.96%)	1 / 51 (1.96%)
occurrences (all)	0	1	1
Otitis Media			
subjects affected / exposed	0 / 7 (0.00%)	1 / 51 (1.96%)	1 / 51 (1.96%)
occurrences (all)	0	1	2

Bacterial Diarrhoea			
subjects affected / exposed	0 / 7 (0.00%)	1 / 51 (1.96%)	0 / 51 (0.00%)
occurrences (all)	0	1	0
Enteritis Infectious			
subjects affected / exposed	0 / 7 (0.00%)	1 / 51 (1.96%)	0 / 51 (0.00%)
occurrences (all)	0	1	0
Furuncle			
subjects affected / exposed	0 / 7 (0.00%)	1 / 51 (1.96%)	0 / 51 (0.00%)
occurrences (all)	0	1	0
Gastroenteritis Viral			
subjects affected / exposed	0 / 7 (0.00%)	1 / 51 (1.96%)	0 / 51 (0.00%)
occurrences (all)	0	1	0
Hand-Foot-And-Mouth Disease			
subjects affected / exposed	0 / 7 (0.00%)	1 / 51 (1.96%)	0 / 51 (0.00%)
occurrences (all)	0	1	0
Mumps			
subjects affected / exposed	1 / 7 (14.29%)	0 / 51 (0.00%)	0 / 51 (0.00%)
occurrences (all)	1	0	0
Nasal Vestibulitis			
subjects affected / exposed	0 / 7 (0.00%)	1 / 51 (1.96%)	0 / 51 (0.00%)
occurrences (all)	0	1	0
Oral Herpes			
subjects affected / exposed	0 / 7 (0.00%)	1 / 51 (1.96%)	0 / 51 (0.00%)
occurrences (all)	0	1	0
Otitis Media Acute			
subjects affected / exposed	0 / 7 (0.00%)	1 / 51 (1.96%)	0 / 51 (0.00%)
occurrences (all)	0	1	0
Pharyngitis			
subjects affected / exposed	0 / 7 (0.00%)	0 / 51 (0.00%)	1 / 51 (1.96%)
occurrences (all)	0	0	1
Varicella			
subjects affected / exposed	0 / 7 (0.00%)	1 / 51 (1.96%)	0 / 51 (0.00%)
occurrences (all)	0	1	0
Metabolism and nutrition disorders			
Decreased Appetite			

subjects affected / exposed occurrences (all)	0 / 7 (0.00%) 0	0 / 51 (0.00%) 0	1 / 51 (1.96%) 1

More information

Substantial protocol amendments (globally)

Were there any global substantial amendments to the protocol? No

Interruptions (globally)

Were there any global interruptions to the trial? No

Limitations and caveats

None reported